Telemedicine for Pediatric Inflammatory Bowel Disease in the Era of COVID‐19
Sofia G. Verstraete, A. Søla, Sabina Ali
Abstract
After 1 month, pruritus disappeared and sBA normalized (4.6 mmol/L). Follow-up at 3 and 8 months confirmed the absence of pruritus and cholestasis (sBA: 1.9 and 5 mmol/L). Serum liver tests, alpha-fetoprotein level, and liver elastography value (Supersonic Shear Imaging: 6 kPa) were normal. This report shows that in our PFIC2 patient GPB is as efficient as PBA to improve pruritus and cholestasis and allows good oral tolerance and therapeutic adherence.
Topics & Concepts
MedicineTelemedicineTelehealthTriageMedical emergencyPandemicHealth careMEDLINEPopulationDiseaseIntensive care medicineCoronavirus disease 2019 (COVID-19)Internal medicineInfectious disease (medical specialty)Economic growthPolitical scienceEnvironmental healthLawEconomicsTelemedicine and Telehealth ImplementationCOVID-19 and healthcare impactsMobile Health and mHealth Applications